After a successful partnership of 10 years with its local distributor ACTS do Brasil Ltda., effective immediately Biosafe has acquired all ACTS’ Biosafe-related business, which has been spun off into a separate operating entity, Biosafe Brasil Distribuidora Ltda. Terms have not been disclosed.
This move will allow Biosafe to offer an extended range of benefits to customers in Brazil, including direct product support and service.
Today most public and private cord blood banks throughout the country already process with Biosafe’s proprietary Sepax technology, which is also used by a number of customers for regenerative medicine applications.
Olivier Waridel, CEO of the Biosafe Group commented: “We firmly believe in the potential of the Brazilian market and this acquisition will further expand our business in our core markets of stem cell banking, regenerative medicine and bioprocessing. We look forward to strengthening our relationship with existing and future customers, and to assisting them with their development.”
Elsewhere in Latin America, Biosafe products are sold through distributors in Mexico, Argentina, Colombia and Chile. Biosafe plans to extend the network to additional countries in the near future.
About the Biosafe Group
Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquartered in Switzerland and privately-owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and São Paulo) and is present in more than 50 countries, either directly or through distributors.
For further information:
Christopher Bolton
CFO
Biosafe Group SA
+41-22-365-27-27